Stereotaxis Stock Earnings Reports

Stereotaxis reported Q1 2026 revenue of $6.3M (system $1.3M, recurring $5.0M), with gross margin 60% and operating loss of $6.0M (adjusted operating loss $2.9M). The quarter was impacted by the transition away from legacy Johnson & Johnson catheter supply and limited initial production of the new MAGiC catheter family, though commercial "green shoots" have begun. Major recent milestones: multiple FDA and international approvals (including MAGiC ablation catheter and Synchrony digital surgery cockpit), first MAGiC procedures completed in the U.S., initial Synchrony orders and shipments, FDA-cleared GenesisX robot (designed to work with existing X-ray systems), and the acquisition of Robocath to broaden robotic capabilities. Management expects manufacturing ramp (contract manufacturer targeting ~500 catheters/month by year-end), meaningful recurring disposable revenue per procedure (reported >$5,000–$8,000 in early MAGiC cases), and reiterates guidance for double-digit revenue growth with annual revenue expected to exceed $40M and sequential quarterly ramp with Q3 and Q4 each above $10M. Cash was $14.6M at quarter-end with no debt; company used an ATM opportunistically to bolster the balance sheet and expects to grow without significant dilution. Key near-term drivers: ramping MAGiC production and disposables revenue, placing Genesis/GenesisX systems (including proving GenesisX compatibility with nonintegrated X-rays), commercial expansion of Synchrony, and integration of Robocath technologies. Risks: manufacturing ramp constraints, transition noise from ending the J&J relationship, and typical early-stage commercialization execution risks.